Syros Pharmaceuticals’ (SYRS) “Hold” Rating Reiterated at TD Cowen

TD Cowen restated their hold rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report sent to investors on Wednesday, MarketBeat Ratings reports.

Several other equities analysts have also recently commented on the company. Piper Sandler restated an “overweight” rating and set a $5.00 target price (down from $13.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, August 13th. JMP Securities lowered their price objective on shares of Syros Pharmaceuticals from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Syros Pharmaceuticals in a research note on Friday, November 1st. Finally, StockNews.com cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Trading Down 5.7 %

Shares of SYRS opened at $0.26 on Wednesday. Syros Pharmaceuticals has a twelve month low of $0.25 and a twelve month high of $8.17. The stock has a market cap of $6.96 million, a PE ratio of -0.09 and a beta of 1.59. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97. The business’s 50-day moving average price is $2.02 and its 200-day moving average price is $3.79.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter in the previous year, the firm posted ($1.35) EPS. On average, equities analysts forecast that Syros Pharmaceuticals will post -2.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Jason Haas purchased 45,344 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was acquired at an average price of $1.68 per share, with a total value of $76,177.92. Following the transaction, the chief financial officer now directly owns 124,552 shares of the company’s stock, valued at approximately $209,247.36. This represents a 57.25 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Conley Chee acquired 50,000 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was purchased at an average price of $1.51 per share, for a total transaction of $75,500.00. Following the transaction, the chief executive officer now directly owns 72,504 shares of the company’s stock, valued at approximately $109,481.04. This trade represents a 222.18 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 130,707 shares of company stock valued at $206,491 over the last three months. Insiders own 12.26% of the company’s stock.

Institutional Investors Weigh In On Syros Pharmaceuticals

Large investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in Syros Pharmaceuticals in the first quarter worth $64,000. GSA Capital Partners LLP purchased a new stake in shares of Syros Pharmaceuticals in the 3rd quarter worth about $34,000. Acadian Asset Management LLC bought a new stake in shares of Syros Pharmaceuticals during the 1st quarter valued at about $91,000. Certuity LLC purchased a new position in shares of Syros Pharmaceuticals during the second quarter valued at about $109,000. Finally, Vanguard Group Inc. lifted its holdings in Syros Pharmaceuticals by 21.3% in the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after buying an additional 163,234 shares during the period. 91.47% of the stock is currently owned by institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.